Abstract Session 9

Co-Chair(s)

• 

  Vania Hungria, MD, PhD (she/her/hers)

  Professor
  Clinica São Germano
  São Paulo, Sao Paulo, Brazil
• 

  Raphael Szalat, MD; PhD (he/him/his)

  Assistant professor of Medicine
  Boston University Chobanian & Avedisian School of Medicine
  Boston, Massachusetts

Presentations:

• 09:00 - 09:10 East Coast USA Time

  (OA-58) Isatuximab Subcutaneous via an on-body Delivery System versus Isatuximab Intravenous, Plus Pomalidomide and Dexamethasone, in Relapsed/Refractory Multiple Myeloma: The Randomized Phase 3 IRAKLIA Study
  

  Abstract Presenter: Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France
• 09:10 - 09:20 East Coast USA Time

  (OA-54) Efficacy of Mezigdomide Plus Dexamethasone and Bortezomib or Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma by Line of Therapy: Results from the Phase 1/2 CC-92480-MM-002 Trial
  

  Abstract Presenter: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
• 09:20 - 09:30 East Coast USA Time

  (OA-57) IVIG and Longer Dosing Intervals Reduce Risk of Infections in Patients with RRMM Treated with Teclistamab
  

  Abstract Presenter: Febe Smits, MD – Department of Hematology, Amsterdam UMC, Amsterdam, The Netherlands
• 09:30 - 09:40 East Coast USA Time

  (OA-59) The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7
  

  Abstract Presenter: Jonathan L. Kaufman, MD – Winship Cancer Institute of Emory University
• 09:40 - 09:50 East Coast USA Time

  (OA-53) Functional High-Risk (FHR) Phenotype Predicts Poor Survival in Multiple Myeloma (MM) Independent of Frontline Treatment: A Secondary CIBMTR Analysis
  

  Abstract Presenter: Rahul Banerjee, MD (he/him/his) – Fred Hutchinson Cancer Center